Company profile
AbbVie logo

AbbVie

Pipeline37 assets

  • ABBV-8736ABBV-8736 / TREM1 / Biologic / Immunology
    Crohn's DiseasePhase 2
  • TavapadonD1/D5 partial agonist / Small molecule / Neuroscience
    Parkinson's DiseaseSubmitted
  • ABBV-525ABBV-525 / MALT1 / Small molecule / Oncology
    Hematologic TumorsPhase 1
  • Telisotuzumab vedotinABBV-399 / EMRELIS / c-Met / Antibody-drug conjugate / Oncology
    Non-Small Cell Lung CancerApprovedUS
  • EpcoritamabGen3013 / EPKINLY/TEPKINLY / CD3, CD20 / Bispecific antibody / Oncology
    Relapsed/Refractory DLBCLApprovedUSEURelapsed/Refractory Follicular LymphomaApprovedRelapsed/Refractory CLLPhase 2
  • ABBV-466 (Skyrizi + ABBV-382)ABBV-466 / SKYRIZI / IL-23 + anti-a4b7 mAb / Biologic combination / Immunology
    Crohn's DiseasePhase 2
  • BudigalimabABBV-181 / PD1 / Biologic / Oncology
    Solid and Hematologic TumorsPhase 2
  • ABBV-701ABBV-701 / TL1A / Biologic / Immunology
    Inflammatory Bowel DiseasePhase 1
  • ABBV-932ABBV-932 / DRD2/DRD3 modulator / Small molecule / Neuroscience
    Bipolar DepressionPhase 2Generalized Anxiety DisorderPhase 2
  • ABBV-9832 (Lutikizumab + Ravagalimab)ABBV-9832 / IL-1a/1b + CD40 antagonist / Biologic combination / Immunology
    Rheumatoid ArthritisPhase 2
  • ABBV-6628ABBV-6628 / C5 / Biologic / Eye Care
    Geographic AtrophyPhase 1
  • ABBV-619ABBV-619 / CD19 / Biologic/CAR-T / Immunology
    Autoimmune diseasesPhase 1
  • LivmoniplimabABBV-151 / GARP-TGF-beta1 / Biologic / Oncology
    Hepatocellular CarcinomaPhase 2Solid TumorsPhase 2Non-Small Cell Lung CancerPhase 2
  • Armour ThyroidArmour Thyroid / T3T4 / Biologic / Other Specialties
    HypothyroidismPhase 3
  • ABBV-319ABBV-319 / CD19 / Biologic ADC / Immunology
    Sjogren's diseasePhase 1Systemic Lupus ErythematosusPhase 1
  • ABBV-722ABBV-722 / LPAR1 / Small molecule / Immunology
    Idiopathic Pulmonary FibrosisPhase 1Systemic SclerosisPhase 1
  • ABBV-142ABBV-142 / LPAR1 / Biologic / Immunology
    Idiopathic Pulmonary FibrosisPhase 1
  • ABBV-324ABBV-324 / Biologic ADC / Oncology
    Solid TumorsPhase 1
  • ABBV-295ABBV-295 / Long-Acting Amylin Analog / Large molecule / Other Specialties
    ObesityPhase 1
  • SurzetoclaxABBV-453 / BCL-2 / Small molecule / Oncology
    Relapsed/Refractory Multiple MyelomaPhase 1
  • ABBV-2002ABBV-2002 / PAR-2 / Biologic / Neuroscience
    MigrainePhase 2
  • IcalcaprantABBV-1354 / KOR antagonist / Small molecule / Neuroscience
    Bipolar DepressionPhase 2Major Depressive DisorderPhase 2
  • ABBV-1042ABBV-1042 / M4 receptor / Small molecule / Neuroscience
    Bipolar ManiaPhase 1
  • Surabgene LomparvovecABBV-RGX-314 / VEGF / Gene therapy / Eye Care
    wet AMD (subretinal)Phase 3wet AMD (suprachoroidal)Phase 2Diabetic Retinopathy (suprachoroidal)Phase 2
  • UbrogepantUBRELVY / CGRP receptor / Small molecule / Neuroscience
    Menstrual MigrainePhase 3
  • ABBV-2001ABBV-2001 / BCMA, CD38, CD3 / Biologic trispecific T-cell engager / Oncology
    Relapsed/Refractory Multiple MyelomaPhase 1
  • Pivekimab SunirinePVEK / CD123 / Biologic ADC / Oncology
  • Mirvetuximab soravtansineELAHERE / FR-alpha / Biologic ADC / Oncology
    Platinum-Resistant Ovarian CancerApprovedPlatinum-Sensitive Ovarian CancerPhase 3
  • AtogepantQULIPTA / CGRP receptor / Small molecule / Neuroscience
    Acute MigraineSubmittedOUSMenstrual MigrainePhase 3OUS
  • EmraclidineM4 PAM / Small molecule / Neuroscience
    SchizophreniaPhase 2PsychosisPhase 1
  • UpadacitinibABT-494 / RINVOQ / JAK1 / Small molecule / Immunology
    Alopecia AreataSubmittedUSEUHidradenitis SuppurativaPhase 3Systemic Lupus ErythematosusPhase 3
  • ABBV-166 (Skyrizi + Lutikizumab)ABBV-166 / SKYRIZI / IL-23 + IL-1a/1b / Biologic combination / Immunology
    Psoriatic ArthritisPhase 2
  • ABBV-848ABBV-848 / IRAK4 / Small molecule / Immunology
    Rheumatoid ArthritisPhase 1
  • ABBV-706ABBV-706 / SEZ6 / Biologic ADC / Oncology
    First Line Small Cell Lung CancerPhase 2Relapsed/Refractory Small Cell Lung CancerPhase 3Neuroendocrine NeoplasmsPhase 1
  • ABBV-1480ABBV-1480 / PD-1, VEGF / Biologic bispecific antibody / Oncology
    Solid TumorsPhase 1
  • LutikizumabABT-981 / IL-1a/1b / Biologic / Immunology
    Hidradenitis SuppurativaPhase 3
  • GemibotulinumtoxinAGemibotA / SNAP-25 / Biologic / Neuroscience
    Ventral Hernia RepairPhase 2

Latest news8 items

All news

AbbVie to Present at the Bank of America Securities Healthcare Conference

NORTH CHICAGO, Ill., May 6, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Bank of America Securities Healthcare Conference on Wednesday, May 13, 2026. Management will participate in a fireside chat at 1:20 p.m. Central Time. A live audio webcast of the presentation will be

AbbVie Reports First-Quarter 2026 Financial Results

Reports First-Quarter Diluted EPS of $0.39 on a GAAP Basis, a Decrease of 45.8 Percent; Adjusted Diluted EPS of $2.65, an Increase of 7.7 Percent; These Results Include an Unfavorable Impact of $0.41 Per Share Related to Acquired IPR&D and Milestones Expense Delivers First-Quarter Net Revenues of

AbbVie to Host First-Quarter 2026 Earnings Conference Call

NORTH CHICAGO, Ill., March 31, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its first-quarter 2026 financial results on Wednesday, April 29, 2026, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time.

AbbVie to Present at the Leerink Partners Global Healthcare Conference

NORTH CHICAGO, Ill., March 3, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Leerink Partners Global Healthcare Conference on Tuesday, March 10, 2026. Management will participate in a fireside chat at 10:20 a.m. Central Time. A live audio webcast of the presentation will be

AbbVie to Present at the TD Cowen 46th Annual Health Care Conference

NORTH CHICAGO, Ill., Feb. 24, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026. Management will participate in a fireside chat at 10:10 a.m. Central Time. A live audio webcast of the presentation will be

AbbVie Reports Full-Year and Fourth-Quarter 2025 Financial Results

Reports Full-Year Diluted EPS of $2.36 on a GAAP Basis, a Decrease of 1.3 Percent; Adjusted Diluted EPS of $10.00, a Decrease of 1.2 Percent; These Results Include an Unfavorable Impact of $2.76 Per Share Related to 2025 Acquired IPR&D and Milestones Expense Delivers Full-Year Net Revenues of

AbbVie to Host Full-Year and Fourth-Quarter 2025 Earnings Conference Call

NORTH CHICAGO, Ill. , Jan. 7, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its full-year and fourth-quarter 2025 financial results on Wednesday, February 4, 2026 , before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time .

AbbVie to Present at the 44th Annual J.P. Morgan Healthcare Conference

NORTH CHICAGO, Ill. , Jan. 5, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 . Management will participate in a fireside chat at 10:15 a.m. Central time . A live audio webcast of the presentation will be

AbbVie • Endpoint Arena